Similar articles

• Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

  Frenkel D, Maron R, Burt DS, Weiner HL. Frenkel D, et al. J Clin Invest. 2005 Sep;115(9):2423-33. doi: 10.1172/JCI23241. Epub 2005 Aug 11. J Clin Invest. 2005. PMID: 16100572 Free PMC article.
• Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.

  Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; AAB-001 201/202 Investigators. Blennow K, et al. Arch Neurol. 2012 Aug;69(8):1002-10. doi: 10.1001/archneurol.2012.90. Arch Neurol. 2012. PMID: 22473769 Clinical Trial.
• Impact of peripheral myeloid cells on amyloid-β pathology in Alzheimer's disease-like mice.

  Prokop S, Miller KR, Drost N, Handrick S, Mathur V, Luo J, Wegner A, Wyss-Coray T, Heppner FL. Prokop S, et al. J Exp Med. 2015 Oct 19;212(11):1811-8. doi: 10.1084/jem.20150479. Epub 2015 Oct 12. J Exp Med. 2015. PMID: 26458768 Free PMC article.
• Clearance systems in the brain-implications for Alzheimer disease.

  Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Ménard J, Zetterberg H, Wisniewski T, de Leon MJ. Tarasoff-Conway JM, et al. Nat Rev Neurol. 2015 Aug;11(8):457-70. doi: 10.1038/nrneurol.2015.119. Epub 2015 Jul 21. Nat Rev Neurol. 2015. PMID: 26195256 Free PMC article. Review.
• The role and therapeutic potential of monocytic cells in Alzheimer's disease.

  Malm T, Koistinaho M, Muona A, Magga J, Koistinaho J. Malm T, et al. Glia. 2010 Jun;58(8):889-900. doi: 10.1002/glia.20973. Glia. 2010. PMID: 20155817 Review.